192 related articles for article (PubMed ID: 17340994)
21. Combining quinupristin/dalfopristin with other agents for resistant infections.
Brown J; Freeman BB
Ann Pharmacother; 2004 Apr; 38(4):677-85. PubMed ID: 14990776
[TBL] [Abstract][Full Text] [Related]
22. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
23. [The frequency of the occurrence of genes ermA, ermB, ermC and msrA/B among methicillin-resistant Staphylococcus aureus strains resistant to erythromycin].
Młynarczyk G; Młynarczyk A; Szymanek K; Luczak M
Med Dosw Mikrobiol; 2006; 58(3):183-90. PubMed ID: 17340992
[TBL] [Abstract][Full Text] [Related]
24. Macrolide-lincosamide-streptogramin B resistance phenotypes and genotypes among Staphylococcus aureus clinical isolates in Japan.
Otsuka T; Zaraket H; Takano T; Saito K; Dohmae S; Higuchi W; Yamamoto T
Clin Microbiol Infect; 2007 Mar; 13(3):325-7. PubMed ID: 17391391
[TBL] [Abstract][Full Text] [Related]
25. [Reduced susceptibility to triclosan in methicillin-resistant Staphylococcus aureus].
Wiśniewska K; Piechowicz L; Galiński J
Med Dosw Mikrobiol; 2006; 58(1):11-7. PubMed ID: 16871968
[TBL] [Abstract][Full Text] [Related]
26. [Predominance of multidrug resistant strains with reduced susceptibility to fusidic acid among methicillin-resistant Staphylococcus aureus strains (MRSA) isolated in the Gdánsk region].
Wiśniewska K; Piechowicz L; Galiński J
Pol Merkur Lekarski; 2000 Nov; 9(53):746-50. PubMed ID: 11204320
[TBL] [Abstract][Full Text] [Related]
27. [Prevalence of inducible clindamycin resistance in Staphylococcus aureus strains isolated from clinical samples].
Colakoğlu S; Alişkan H; Turunç T; Demiroğlu YZ; Arslan H
Mikrobiyol Bul; 2008 Jul; 42(3):407-12. PubMed ID: 18822883
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
29. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report.
Orrett FA
Jpn J Infect Dis; 2008 Mar; 61(2):107-10. PubMed ID: 18362397
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.
Reinert RR; Kresken M; Mechery V; Lemperle M; Lütticken R
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):662-5. PubMed ID: 9832271
[TBL] [Abstract][Full Text] [Related]
31. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Bogdanovich T; Clark C; Kosowska-Shick K; Dewasse B; McGhee P; Appelbaum PC
Antimicrob Agents Chemother; 2007 Nov; 51(11):4191-5. PubMed ID: 17875997
[TBL] [Abstract][Full Text] [Related]
32. Mupirocin resistance among Iranian isolates of Staphylococcus aureus.
Saderi H; Owlia P; Habibi M
Med Sci Monit; 2008 Oct; 14(10):BR210-3. PubMed ID: 18830185
[TBL] [Abstract][Full Text] [Related]
33. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides.
Werner G; Cuny C; Schmitz FJ; Witte W
J Clin Microbiol; 2001 Oct; 39(10):3586-90. PubMed ID: 11574577
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of mupirocin and an isoflavanone isolated from Erythrina variegata on growth and recovery of methicillin-resistant Staphylococcus aureus.
Sato M; Tanaka H; Yamaguchi R; Kato K; Etoh H
Int J Antimicrob Agents; 2004 Sep; 24(3):241-6. PubMed ID: 15325427
[TBL] [Abstract][Full Text] [Related]
35. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods.
Boswell FJ; Sunderland J; Andrews JM; Wise R
J Antimicrob Chemother; 1997 May; 39 Suppl A():29-32. PubMed ID: 9511059
[TBL] [Abstract][Full Text] [Related]
36. Inducible clindamycin resistance in staphylococci isolated from clinical samples.
Delialioglu N; Aslan G; Ozturk C; Baki V; Sen S; Emekdas G
Jpn J Infect Dis; 2005 Apr; 58(2):104-6. PubMed ID: 15858290
[TBL] [Abstract][Full Text] [Related]
37. [Mupirocin resistance in methicillin-resistant Staphylococcus aureus strains isolated from wound infections].
Dolapçi I; Karahan ZC; Tekeli A; Koyuncu E; Azap A; Adaleti R
Mikrobiyol Bul; 2007 Jul; 41(3):435-40. PubMed ID: 17933255
[TBL] [Abstract][Full Text] [Related]
38. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.
Bébéar C; Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():59-62. PubMed ID: 9511064
[TBL] [Abstract][Full Text] [Related]
39. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
Fantin B; Leclercq R; Garry L; Carbon C
Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
